---
title: "Pediatric pharmacogenomics from whole-exome sequencing: age‑aware interpretation in 1,159 Russian"
id: "medrxiv-4-pediatric-pharmacogenomics-from-whole-exome-sequencing-developmentally"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-4-pediatric-pharmacogenomics-from-whole-exome-sequencing-developmentally"
content_type: "clinical_feed_article"
specialty: "Pediatrics"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.21.26360945v1?rss=1"
published_at: "2026-08-25T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Pediatric pharmacogenomics from whole-exome sequencing: age‑aware interpretation in 1,159 Russian
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-4-pediatric-pharmacogenomics-from-whole-exome-sequencing-developmentally
- **Specialty:** [Pediatrics](https://medichelpline.com/clinical-feed/pediatrics.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.21.26360945v1?rss=1)
- **Published At:** 2026-08-25T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Study evaluated the clinical usefulness of **pharmacogenomics (PGx)** derived from **whole-exome sequencing (WES)** in 1,159 Russian pediatric subjects (524 children and 635 newborns). - Researchers filtered PGx annotations by PharmGKB/ClinPGx evidence levels (1A–2B) and the presence of a 'Pediatrics' tag to identify clinically relevant variants. - Clinically actionable annotations that would prompt drug avoidance or dose modification represented only 5% of initial PGx annotations in both cohorts. - Of those clinically relevant annotations, about two-thirds in each cohort were alleles associated with altered function (67.6% pediatric; 67.2% neonatal). - Concordance between genotype-based recommendations and the ontogenetic status of drug-metabolizing enzymes in newborns was low: concordance observed for 5 of 14 gene–drug pairs (35.71%). - In a retrospective review of 100 pediatric patients, adverse drug reactions (ADRs) were recorded in 21% of patients; only two ADR cases could be explained by high-evidence PharmGKB/ClinPGx annotations. - A 'PGx–ADR–cost' database was compiled and a relative population burden index calculated for 27 gene–variant–drug–ADR associations; top-ranked associations included **UGT1A1*28–irinotecan-induced neutropenia** and **HLA-A*31:01–carbamazepine-induced severe cutaneous reactions**. - Authors conclude that age and **ontogeny** critically affect interpretation of pediatric PGx and that adult-focused algorithms are insufficient for children and newborns. - The paper proposes a pediatric PGx interpretation model requiring patient age reporting, ontogenetic adjustment, evidence-level stratification, and multidisciplinary clinical assessment, and calls for prospective validation. - Ethical approvals, consent procedures, and data access restrictions for individual-level genomic data are reported; individual-level sequence data are available on reasonable request subject to approvals and national regulations.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=qmY0U6acGi3B5z8La5uGHwcXLuqkb5YSWd2HFB.JueQ-1787676565.8605437-1.2.1.1-VOnN1O5A1H.IL5bMdWBfFmCDe3A4ovpThlZlu.KSSfX5B0eYOBGtK_Jfi3Acqt3D) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.21.26360945v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Pediatric pharmacogenomics from whole-exome sequencing: developmentally appropriate interpretation in 1,159 Russian children and newborns [ View ORCID Profile](http://orcid.org/0000-0001-7894-9222)Anastasiia A. Buianova, [ View ORCID Profile](http://orcid.org/0000-0001-5294-3033)Valery V. Cheranev, Mikhail Iu. Kuznetsov, [ View ORCID Profile](http://orcid.org/0009-0007-4228-6114)Zhanna A. Repinskaia, [ View ORCID Profile](http://orcid.org/0000-0001-5930-1965)Vera A. Belova doi: https://doi.org/10.64898/2026.08.21.26360945 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Anastasiia A. Buianova Pirogov Russian National Research Medical University, Moscow, Russian Federation * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Anastasiia%2BA.%2BBuianova%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Buianova%20AA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAnastasiia%2BA.%2BBuianova%2B) * [ORCID record for Anastasiia A. Buianova](http://orcid.org/0000-0001-7894-9222 "Open in new tab") * For correspondence: anastasiiabuianova97@gmail.com Valery V. Cheranev Pirogov Russian National Research Medical University, Moscow, Russian Federation * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Valery%2BV.%2BCheranev%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Cheranev%20VV&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AValery%2BV.%2BCheranev%2B) * [ORCID record for Valery V. Cheranev](http://orcid.org/0000-0001-5294-3033 "Open in new tab") Mikhail Iu. Kuznetsov Pirogov Russian National Research Medical University, Moscow, Russian Federation * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Mikhail%2BIu.%2BKuznetsov%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kuznetsov%20MI&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMikhail%2BIu.%2BKuznetsov%2B) Zhanna A. Repinskaia Pirogov Russian National Research Medical University, Moscow, Russian Federation * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Zhanna%2BA.%2BRepinskaia%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Repinskaia%20ZA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AZhanna%2BA.%2BRepinskaia%2B) * [ORCID record for Zhanna A. Repinskaia](http://orcid.org/0009-0007-4228-6114 "Open in new tab") Vera A. Belova Pirogov Russian National Research Medical University, Moscow, Russian Federation * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Vera%2BA.%2BBelova%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Belova%20VA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AVera%2BA.%2BBelova%2B) * [ORCID record for Vera A. Belova](http://orcid.org/0000-0001-5930-1965 "Open in new tab") * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.21.26360945v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1285717/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.21.26360945v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1285717/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.21.26360945v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1285717/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.08.21.26360945v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1285717/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.21.26360945v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1285717/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.21.26360945v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1285717/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Introduction: The application of pharmacogenomics (PGx) in pediatrics is limited by the lack of age-oriented interpretation approaches, as algorithms developed for adults do not account for ontogenetic changes in the activity of drug-metabolizing enzymes and transport proteins. The aim of this study was to evaluate the clinical applicability of pharmacogenomic data in Russian children, assess the concordance between genotype-based recommendations and the ontogenetic status of drug-metabolizing enzymes, and develop recommendations for the generation of age-oriented PGx reports. Methods: We analyzed whole-exome sequencing (WES) data from 524 pediatric patients and 635 newborns, filtering pharmacogenomic annotations according to PharmGKB/ClinPGx evidence levels (1A–2B) and the presence of the 'Pediatrics' tag. The concordance between genotype-based recommendations and the ontogenetic status of drug-metabolizing enzymes was assessed in newborns. In a pediatric subgroup of 100 patients, a retrospective analysis of medical records was performed to evaluate the structure of pharmacotherapy and the frequency of adverse drug reactions (ADRs). A 'PGx–ADR–cost' database was created, and the relative population burden index was calculated for 27 gene–variant–drug–ADR associations. Results: Clinically relevant annotations (requiring drug avoidance or dose modification) accounted for only 5% of all initial pharmacogenomic annotations in both cohorts; 67.6% (pediatric cohort) and 67.2% (neonatal cohort) of these were related to alleles with altered function. Concordance between genotype-based recommendations and the ontogenetic status of drug-metabolizing enzymes in newborns was observed in only 5 of 14 (35.71%) gene–drug pairs. ADRs were identified in 21% of the 100 pediatric patients; however, only two cases could be explained by high-evidence PharmGKB/ClinPGx annotations. Ranking by relative population burden identified UGT1A1*28–irinotecan-induced neutropenia and HLA-A*31:01–carbamazepine-induced severe cutaneous reactions as priority associations. Conclusions: Age represents a critical factor in the interpretation of pharmacogenomic data in children, as current approaches to PGx reporting do not adequately incorporate the ontogenetic context. We propose a pediatric PGx interpretation model that includes mandatory reporting of patient age, ontogenetic adjustment, evidence-level stratification, and multidisciplinary clinical assessment. Prospective validation is required to confirm the clinical utility of the proposed approach. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was conducted in accordance with the Declaration of Helsinki, and approval was obtained from the Local Research Ethics Committee of Russian National Medical University (Protocol No. 241, from 26 June 2024), and all participants provided written informed consent prior to data collection. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability The individual-level DNA sequencing data generated in this study constitute sensitive human genomic data and are subject to legal and ethical restrictions under national regulations governing human genetic data protection in the Russian Federation. Access to individual-level data may be granted upon reasonable request to the corresponding author, subject to approval by the relevant institutional review board and in compliance with applicable legal and ethical requirements. ## Funder Information Declared Ministry of Health of the Russian Federation, reg. No. 126031819012-2, topic “Pharmaceutical development of the gene therapy drug pAAV9-cBIN for the treatment of chronic non‑ischemic heart failure” Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.21.26360945v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.20.26360021v1 "Movement-responsive deep brain stimulation reinforces motor circuits in Parkinson's disease") Posted August 25, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.21.26360945v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/08/25/2026.08.21.26360945.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.21.26360945v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.08.21.26360945v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/08/25/2026.08.21.26360945.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Pediatric pharmacogenomics from whole-exome sequencing: developmentally appropriate interpretation in 1,159 Russian children and newborns Anastasiia A. Buianova, Valery V. Cheranev, Mikhail Iu. Kuznetsov, Zhanna A. Repinskaia, Vera A. Belova medRxiv 2026.08.21.26360945; doi: https://doi.org/10.64898/2026.08.21.26360945 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.21.26360945v1%26text%3DPediatric%2520pharmacogenomics%2520from%2520whole-exome%2520sequencing%253A%2520developmentally%2520appropriate%2520interpretation%2520in%25201%252C159%2520Russian%2520children%2520and%2520newborns "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.21.26360945v1%26t%3DPediatric%2520pharmacogenomics%2520from%2520whole-exome%2520sequencing%253A%2520developmentally%2520appropriate%2520interpretation%2520in%25201%252C159%2520Russian%2520children%2520and%2520newborns "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.21.26360945v1%26title%3DPediatric%2520pharmacogenomics%2520from%2520whole-exome%2520sequencing%253A%2520developmentally%2520appropriate%2520interpretation%2520in%25201%252C159%2520Russian%2520children%2520and%2520newborns%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.21.26360945v1%26title%3DPediatric%2520pharmacogenomics%2520from%2520whole-exome%2520sequencing%253A%2520developmentally%2520appropriate%2520interpretation%2520in%25201%252C159%2520Russian%2520children%2520and%2520newborns "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.08.21.26360945) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.08.21.26360945v1&count=horizontal&via=&text=Pediatric%20pharmacogenomics%20from%20whole-exome%20sequencing%3A%20developmentally%20appropriate%20interpretation%20in%201%2C159%20Russian%20children%20and%20newborns&counturl=www.medrxiv.org/content/10.64898/2026.08.21.26360945v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (611) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (891) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (324) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4746) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (473) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (406) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (639) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1609) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15781) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1193) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (6953) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (724) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1050) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (4951) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1420) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1730) * [Hematology](https://www.medrxiv.org/collection/hematology) (577) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1327) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16224) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1156) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (658) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (150) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (717) * [Neurology](https://www.medrxiv.org/collection/neurology) (7146) * [Nursing](https://www.medrxiv.org/collection/nursing) (360) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1071) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1221) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (996) * [Oncology](https://www.medrxiv.org/collection/oncology) (3561) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1031) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (389) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (443) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (464) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (138) * [Pathology](https://www.medrxiv.org/collection/pathology) (702) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1767) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (730) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (757) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (5807) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9651) * [Radiology and Imaging](https://www.medrxiv.org/collectio
## Related Clinical Research

- [Understanding Hospice Discharge: A Family's Guide](https://medichelpline.com/clinical-feed/kff-health-news-1-my-husband-was-kicked-out-of-hospice-for-dying-too-slowly.md)
- [Retinal changes on OCT may predict atrial fibrillation risk years before diagnosis](https://medichelpline.com/clinical-feed/medical-news-today-0-how-changes-in-the-eyes-may-help-spot-afib-risk-years-early.md)
- [More REM (dream) sleep linked to lower risk of 83 diseases—UK Biobank study](https://medichelpline.com/clinical-feed/medical-news-today-0-more-dream-sleep-linked-to-lower-risk-of-83-diseases-including-diabetes.md)
- [Extended Treatment Duration and Recurrence in Cavitary Drug-Susceptible Pulmonary Tuberculosis](https://medichelpline.com/clinical-feed/plos-one-11-extended-treatment-duration-and-recurrence-in-successfully-treated-drug.md)
- [Officials Tout AI Avatars for Rural Health Amid Skepticism; ARPA-H Backs AI for Heart Failure](https://medichelpline.com/clinical-feed/stat-news-2-oz-says-ai-based-avatars-can-help-rural-communities-some-leaders-disagree.md)

## Navigation
- [← Back to Pediatrics Feed](https://medichelpline.com/clinical-feed/pediatrics.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.